Dasatinib, a second-generation inhibitor of tyrosine kinases, is currently being studied in the initial treatment of Ph+ ALL.
El dasatinib, un inhibidor de la tirosina cinasa de segunda generación, está en estudio para el tratamiento inicial de la LLA Ph+.